Financial Performance - The total operating revenue for the first half of 2025 was approximately CNY 2.10 billion, representing a 2.83% increase compared to CNY 2.04 billion in the same period last year[24]. - The net profit attributable to shareholders decreased by 20.70% to approximately CNY 127.76 million, down from CNY 161.11 million in the previous year[24]. - The basic earnings per share (EPS) fell by 20.00% to CNY 0.48, compared to CNY 0.60 in the same period last year[23]. - The net cash flow from operating activities increased by 41.18% to approximately CNY 160.71 million, up from CNY 113.84 million in the previous year[24]. - The total assets as of the end of the reporting period were approximately CNY 8.38 billion, a 10.57% increase from CNY 7.58 billion at the end of the previous year[24]. - The weighted average return on net assets decreased by 0.72 percentage points to 2.24% compared to 2.96% in the same period last year[23]. - The net profit after deducting non-recurring gains and losses was approximately CNY 117.98 million, a decrease of 26.97% from CNY 161.54 million in the previous year[24]. Profit Distribution and Shareholder Returns - The company will not distribute profits or increase capital reserves through stock conversion for the mid-year of 2025[6]. - The company distributed a cash dividend of 6.50 yuan per 10 shares, totaling 173,109,144 yuan, which represents 44.94% of the net profit attributable to shareholders for the fiscal year 2024[98]. - The company emphasizes the importance of investor returns and aims to enhance the stability and sustainability of its dividend policy[98]. Market Presence and Expansion - The company has established a comprehensive marketing network covering over 9,200 hospitals in China, including more than 1,200 top-tier hospitals[29]. - The company’s products are sold in over 70 countries and regions globally, showcasing its international market presence[29]. - The company has achieved a 99% coverage rate in the top 100 chain pharmacies across the country, with over 210,000 retail outlets[30]. - The company operates 17 online stores across major e-commerce platforms, accumulating a total of 9.5 million followers[30]. - The company is actively expanding into emerging markets such as Southeast Asia, the Middle East, and Africa, leveraging the growing medical demand in these regions[59]. Product Development and Innovation - The company focuses on medical-grade personal care and home health care products, expanding its product line to meet diverse consumer needs[30]. - The company emphasizes innovation in product development, particularly in wound care and infection control products, to enhance patient outcomes[31]. - The company has made significant progress in product innovation, including the development of new antimicrobial materials and modern wound dressings, enhancing its R&D capabilities[61]. - The company is focused on expanding its product offerings in personal protective equipment, including disposable masks and protective clothing[36]. - The company has acquired Ningbo Shengyu Rui Medical Equipment Co., which specializes in respiratory and anesthesia products, enhancing its product portfolio[34]. Financial Management and Risks - The company has established a comprehensive supplier development and management system to ensure the quality of procurement materials[38]. - The company is focused on operational efficiency through lean management and digital tools to enhance supply chain efficiency and reduce costs[56]. - The company is aware of foreign exchange risks due to its international business expansion and is implementing measures to mitigate these risks[94]. - The company faces market risks due to global economic uncertainties and increased competition from lower-cost countries in Southeast Asia[92]. Regulatory Compliance and Governance - The company is committed to improving its quality control capabilities through automation and digitalization initiatives[92]. - The company is focused on improving its governance structure and has completed the election of a new board of directors, ensuring diverse expertise and experience[100]. - The company is committed to enhancing its information disclosure quality and investor relations management, holding performance briefings to communicate with investors[99]. - The company has established measures to ensure compliance with regulatory requirements and will accept penalties for any violations of commitments[116]. Research and Development - The company obtained 4 new Class II medical device registrations and 6 invention patents during the reporting period, bringing the total to 111 invention patents and 140 Class II medical device registrations[62]. - The company’s R&D expenses for the period were CNY 63,735,842.41, a 2.06% increase from CNY 62,452,317.21 in the previous year[73]. - The company is investing approximately ¥65 million in a new medical device production base and research institute, with land acquisition costs of ¥4.51 million already incurred[83]. Financial Position and Assets - Cash and cash equivalents increased to ¥922.96 million, representing 11.02% of total assets, up from ¥596.16 million (7.87%) last year, a growth of 54.82%[77]. - Total assets as of June 30, 2025, amounted to CNY 3,244,278,981.61, an increase from CNY 2,649,819,041.87 as of December 31, 2024[140]. - Total liabilities increased to ¥2,468,419,968.34 from ¥1,680,456,463.01, which is an increase of approximately 47.0%[142]. - The company’s total liabilities remain stable, contributing to a solid financial position[161]. Commitments and Responsibilities - The company will ensure that any profits gained from unfulfilled commitments will be returned to the designated account of the relevant entity within 5 working days[114]. - The company will disclose any unfulfilled commitments in a timely manner through designated media and will provide supplementary or alternative commitments to protect investor rights[114]. - The company will take responsibility for any losses caused to investors by the failure of its directors and senior management to fulfill commitments[114].

证券代码：603301 证券简称：振德医疗 公告编号：2025-032 振德医疗用品股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、会议召开时间：2025 年 9 月 11 日（星期四）10:00-11:00 2、会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 3、会议召开方式：上证路演中心网络互动 4、投资者可于 2025 年 9 月 4 日（星期四）至 9 月 10 日（星期 三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过本公告后附的电话、传真和指定邮箱进行提问。公司将在说明会 上选择投资者普遍关注的问题进行回答。 振德医疗用品股份有限公司（以下简称"公司"）已于 2025 年 8 月 28 日发布公司 2025 年半年度报告。为便于广大投资者更全面深入 地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 9 月 11 日上午 10: ...

振德医疗公告，2025年上半年营业收入21亿元，同比增长2.83%。净利润1.28亿元，同比下降20.70%。 公司2025年中期不进行利润分配或资本公积金转增股本。 ...

8月27日，振德医疗大宗交易成交10万股，成交额232万元，占当日总成交额的2.07%，成交价23.2元，较市场收盘价23.2元持平。 | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | | | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-27 | 振德医疗 | 603301 | 23.2 | 232 10 | 国泰海通证券股份 | 东方证券股份有限 | | | | | | | | 有限公司上海长宁 | 公司芜湖北京中路 | | | | | | | | 区江苏路证券营业 | 证券营业部 | | ...

来源：金融界 最近三个交易日，19日-21日，振德医疗分别获融资买入0.14亿元、0.12亿元、0.17亿元。 融券方面，当日融券卖出0.05万股，净卖出0.05万股。 8月21日，沪深两融数据显示，振德医疗获融资买入额0.17亿元，居两市第1188位，当日融资偿还额0.14 亿元，净买入268.14万元。 ...

Group 1 - The medical device industry experienced a slight increase of 0.07% on August 21, with a net outflow of 596 million yuan in main capital [1] - Among the component stocks, 55 stocks rose while 41 stocks fell [1] - The companies with the highest net outflow of main capital included Xinhua Medical (11.58 million yuan), Libang Instruments (10.77 million yuan), and Jiukang Bio (10.73 million yuan) [1] Group 2 - The latest prices and performance of selected medical companies include: Meihua Medical at 23.41 with an increase of 8.09% and a net inflow of 6.44 million yuan [2] - Mindray Medical at 245.71 with an increase of 3.87% and a net inflow of 879.86 million yuan [2] - Other notable companies include Yingke Medical at 37.43 with an increase of 1.08% and a net inflow of 599.81 million yuan, and Aibo Medical at 77.31 with an increase of 1.15% and a net inflow of 4360.64 million yuan [2]

Core Viewpoint - Zhendermedical's stock closed at 24.6 yuan, up 1.74%, with a rolling PE ratio of 18.06, marking a 215-day low, and a total market value of 6.555 billion yuan [1] Group 1: Company Performance - For Q1 2025, the company reported revenue of 999.2 million yuan, a year-on-year increase of 2.87%, and a net profit of 51.2419 million yuan, a year-on-year decrease of 30.19%, with a gross profit margin of 34.28% [1] - As of March 31, 2025, the number of shareholders increased to 24,690, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2: Industry Comparison - The average PE ratio for the medical device industry is 59.32, with a median of 39.97, placing Zhendermedical at 38th in the industry ranking [1][2] - Other companies in the industry have varying PE ratios, with the highest being 20.96 for Antu Biology and the lowest at 11.61 for Jiuan Medical [2]

融券方面，当日融券卖出0.00万股，净卖出0.00万股。 来源：金融界 8月18日，沪深两融数据显示，振德医疗获融资买入额0.11亿元，居两市第1530位，当日融资偿还额0.12 亿元，净卖出116.62万元。 最近三个交易日，14日-18日，振德医疗分别获融资买入0.08亿元、0.12亿元、0.11亿元。 ...

最近三个交易日，13日-15日，振德医疗分别获融资买入0.19亿元、0.08亿元、0.12亿元。 8月15日，沪深两融数据显示，振德医疗获融资买入额0.12亿元，居两市第1247位，当日融资偿还额0.10 亿元，净买入188.34万元。 融券方面，当日融券卖出0.03万股，净卖出0.02万股。 来源：金融界 ...

Core Viewpoint - Zhendemedical (振德医疗) has experienced a stock price increase of 6.57% this week, closing at 23.68 yuan, with a total market capitalization of 6.31 billion yuan as of August 15, 2025 [1] Company Announcements - The company held its fourth board meeting, electing Mr. Lu Jianguo as chairman and Ms. Shen Zhenfang as vice-chairman, with a term of three years. A new executive team was also appointed, including positions such as general manager and financial officer [1] - The first extraordinary general meeting of 2025 was held on August 11, 2025, in Shaoxing, Zhejiang, where multiple proposals were approved, including the fourth board's remuneration plan and the cancellation of the supervisory board [2] Share Capital Changes - Zhendemedical will cancel 615,667 unvested shares from the first employee stock ownership plan, reducing the total share capital from 266,451,202 shares to 265,835,535 shares [3][4]